Regeneron expects no gross sales of its Covid-19 antibody cocktail REGEN-COV within the first quarter of 2022 now that it has been discovered to be ineffective in opposition to the omicron variant, the corporate’s high executives mentioned throughout a 4Q earnings name Friday.
“We lately introduced that REGEN-COV is extremely unlikely to be lively in opposition to the omicron variant,” mentioned CEO Leonard Schleifer.
Final month, the FDA revoked its emergency use authorization for each Regenron’s and Eli Lilly’s antibody therapies after laboratory research discovered them to be ineffective in opposition to the omicron variant, which now accounts for almost all of the circumstances within the U.S. “It is extremely unlikely that COVID-19 sufferers searching for care within the U.S. at the moment are contaminated with a variant aside from omicron, and these therapies usually are not licensed for use at the moment,” mentioned the FDA in a press launch.
Regenron’s antibody remedy was administered to thousands and thousands of individuals throughout the globe final 12 months. The corporate mentioned it has already delivered the remaining of the 1.4 million doses that had been bought by the united statesgovernment. In 2021, the corporate says its revenues elevated 89% to $16.07 billion in comparison with 2020, with $6.19 billion attributable to REGEN-COV.
Regenron’s focus is on upscaling its new antibodies which have proven to work in opposition to all variants of concern, together with omicron and delta. “We’re scaling up manufacturing efforts and finishing the mandatory necessities to start medical trials,” Schleifer mentioned. Because the pandemic turns endemic, the corporate’s monoclonal antibodies remedy could possibly be used as prevention for immunocompromised sufferers who don’t reply to Covid-19 vaccines, he added.